Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 263

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 263
---
 2027 | December06, 2027      |                                       |                                           |                        82,222 |

(a) Comprises the Chief Executive Officer, and any Deputy Chief Executive Officers or members of the Management Board in office at the date of grant. (b) In office at the date of grant. (c) Subject to the conditions set. (d) 48,885 rights were cancelled due to partial non-fulfillment of performance condition. As of December 31, 2024, 10,515,365 shares had not yet vested pending fulfillment of performance conditions.

| 158 | SANOFIFORM 20-F2024 |

| PART I                                             |
| ITEM 6. Directors, Senior Management and Employees |

Shares Owned by Members of the Board of Directors As of December 31, 2024, members of our Board of Directors held in the aggregate 155,251 shares, or under 1% of the share capital and of the voting rights, excluding the beneficial ownership of 118,227,307 shares held by L’Oréal as of such date which may be attributed to Barbara Lavernos or Christophe Babule (who disclaim beneficial ownership of such shares) . Transactions in Shares by Members of the Board of Directors and Equivalent Persons in 2024 and early 2025 As far as Sanofi is aware, transactions in our securities carried out during 2024 and early 2025 by (i) Board members, (ii) executives with the power to make management decisions affecting our future development and corporate strategy and (iii) persons with close personal ties to such individuals (as per Article L. 621-18-2 of the French Monetary and Financial Code), were as follows: • April 26, 2024: Antoine Yver, director, acquired 1,000 shares at a price of €91.38 per share, and concomitantly sold 2,000 ADSs ( American Depositary Shares ); • May 2, 2024: Paul Hudson, Chief Executive Officer, acquired 71,423 restricted shares; • June 21, 2024: John Sundy, director, acquired 887 ADSs at a price of $46.94 per ADS; • September 16, 2024: Anne-Françoise Nesmes, director, acquired 533 shares at a price of £87.02 per share; • October 31, 2024: Clotilde Delbos, director, acquired 500